GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Innogene Co Ltd (XKRX:344860) » Definitions » Capex-to-Operating-Cash-Flow

Innogene Co (XKRX:344860) Capex-to-Operating-Cash-Flow : 0.00 (As of Sep. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Innogene Co Capex-to-Operating-Cash-Flow?

Capex-to-Operating-Cash-Flow assesses how much of a company’s cash flow from operations is being devoted to capital expenditure. It’s also useful to distinguish whether the company is capital intensive or not.

Innogene Co's Capital Expenditure for the three months ended in Sep. 2024 was ₩0.00 Mil. Its Cash Flow from Operations for the three months ended in Sep. 2024 was ₩264.37 Mil.

Hence, Innogene Co's Capex-to-Operating-Cash-Flow for the three months ended in Sep. 2024 was 0.00.


Innogene Co Capex-to-Operating-Cash-Flow Historical Data

The historical data trend for Innogene Co's Capex-to-Operating-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Innogene Co Capex-to-Operating-Cash-Flow Chart

Innogene Co Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Capex-to-Operating-Cash-Flow
Get a 7-Day Free Trial 0.03 0.02 - 0.06 0.02

Innogene Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Capex-to-Operating-Cash-Flow Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 0.01 - - -

Competitive Comparison of Innogene Co's Capex-to-Operating-Cash-Flow

For the Biotechnology subindustry, Innogene Co's Capex-to-Operating-Cash-Flow, along with its competitors' market caps and Capex-to-Operating-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Innogene Co's Capex-to-Operating-Cash-Flow Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Innogene Co's Capex-to-Operating-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Innogene Co's Capex-to-Operating-Cash-Flow falls into.



Innogene Co Capex-to-Operating-Cash-Flow Calculation

Innogene Co's Capex-to-Operating-Cash-Flow for the fiscal year that ended in Dec. 2023 is calculated as

Capex-to-Operating-Cash-Flow=- Capital Expenditure / Cash Flow from Operations
=- (-47.842) / 2236.101
=0.02

Innogene Co's Capex-to-Operating-Cash-Flow for the quarter that ended in Sep. 2024 is calculated as

Capex-to-Operating-Cash-Flow=- Capital Expenditure / Cash Flow from Operations
=- (0) / 264.366
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Innogene Co  (XKRX:344860) Capex-to-Operating-Cash-Flow Explanation

Capex-to-Operating-Cash-Flow ratio assesses how much of a company’s Cash Flow from Operations is being devoted to Capital Expenditure. It is a good indicator in terms of how much the company is focused on growth. In general, a high Capex-to-Operating-Cash-Flow ratio indicates that the company is investing more in physical assets and is focused on growth and expansion. Conversely, lower ratio could indicate that a company has reached maturity and is no longer pursuing aggressive growth.

Moreover, the ratio is also useful to distinguish whether the company is capital intensive or not. If the ratio is large, then the company tends to be capital intensive. Lower ratio suggests that it’s a capital-light business. The ratio can be combined with ROIC % to identify whether the company is an asset-light business that has a high return on invested capital. This is one question investors commonly ask to see if a company qualifies as a good company.


Innogene Co Capex-to-Operating-Cash-Flow Related Terms

Thank you for viewing the detailed overview of Innogene Co's Capex-to-Operating-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.


Innogene Co Business Description

Traded in Other Exchanges
N/A
Address
No. 301, 28, Digital-ro 33-gil, Guro-gu, Seoul, KOR
Innogene Co Ltd is a bio-technology company. The company provides treatment solutions using stem cells and databases for hair loss, psoriasis, skin regeneration and hair follicle formation. Also, the company helps in hair loss diagnosis.

Innogene Co Headlines

No Headlines